Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 7/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499269 | 0.94 | STING1 (0.38) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL18521646 | 0.92 | STING1 (0.37) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL18511033 | 0.92 | STING1 (0.37) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL24499642 | 0.92 | STING1 (0.37) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL22381960 | 0.90 | STING1 (0.46) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL24499551 | 0.90 | STING1 (0.46) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL18520923 | 0.90 | STING1 (0.46) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL22399551 | 0.87 | POLB (0.38) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL18510973 | 0.87 | POLB (0.38) | STING1POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL22381666 | 0.87 | STING1 (0.36) | STING1POLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | STING1 1/4885POLB 240/4885P2RY2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.